Drug Trial Radar · NCT07914738
A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study will evaluate how the body takes in lepodisiran (LY3819469) after a single injection under the skin. Researchers will compare how much lepodisiran gets into the body from each injection site. The study will also look at how safe lepodisiran is and how it affects lipoprotein(a) (Lp(a)), in healthy adults who have high Lp(a) levels. Participants will take part in the study for about 17 weeks. Participants will be admitted to the clinical research unit on Day -1 and remain confined until discharge on Day 4. The study drug will be administered on Day 1. Participants will return to the clinical research unit for outpatient visits on Days 8, 15, 29, and 57.
Conditions
- Lipoprotein(a)
Interventions
LY3819469Drug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LY3819469Time frame: Day 1 through Day 15
- PK: Area Under the Concentration versus Time Curve (AUC) of LY3819469Time frame: Day 1 through Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lilly Centre for Clinical Pharmacology
Singapore, Singapore · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.